Evidence map›Paper›PMID 37786560›Full record

ReviewIbrain2021

Application value and challenge of traditional Chinese medicine carried by ZIF-8 in the therapy of ischemic stroke.

Xiao-Xi Zhu, Dong-Fen Guo, Ming Chen, Xiao-Qiong An, Bi Wang, Wen-Feng Yu

Abstract readReview
In one paragraph

Review in Ibrain, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiao-Xi ZhuKey Laboratory of Molecular Biology Guizhou Medical University Guiyang Guizhou China.
Dong-Fen GuoKey Laboratory of Molecular Biology Guizhou Medical University Guiyang Guizhou China.
Ming ChenKey Laboratory of Molecular Biology Guizhou Medical University Guiyang Guizhou China.
Xiao-Qiong AnKey Laboratory of Molecular Biology Guizhou Medical University Guiyang Guizhou China.
Bi WangKey Laboratory of Molecular Biology Guizhou Medical University Guiyang Guizhou China.
Wen-Feng YuKey Laboratory of Molecular Biology Guizhou Medical University Guiyang Guizhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is a group of major diseases that cause death or disability in adults, with high incidence and lack of available therapeutic strategies. Although traditional Chinese medicine (TCM) has continuously achieved good effects in the therapy of stroke while there is still not convincing due to the limitation of blood-brain permeability, as well as the individual differences in usage and dosage. With the improvement of nanotechnology, TCM nanopreparation has gradually become a research hotspot in various fields due to its advantages in permeating the blood-brain barrier, targeting delivery, enhancing sustained-release drug delivery, changing the distribution in the body, and improving bioavailability. Zeolitic imidazolate framework-8 (ZIF-8) is an ideal nano-drug delivery system for adsorption, catalysis, and drug loading, which is a biocompatible metal-organic framework framed by 2-methylimidazole and zinc ions. At present, ZIF-8 was wildly used in the treatment of ischemic stroke. However, challenges remain persists for its clinical application, such as preparation technology, detection technology in vivo, targeting specificity, safety and stability, and so forth. Therefore, more efforts need to overcome the above problems to develop the application of TCM nanopreparations in the therapy of ischemia/reperfusion in the future.

Indexed as

ischemic strokenanopreparationtraditional Chinese medicinezeolitic imidazolate framework‐8

Identifiers

PMID37786560
PMCPMC10529174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.